EU consortium advances secretome-based therapy for osteoarthritis
The ExoCordOA consortium has announced the launch of a five-year, €13 million project, funded by Horizon Europe to advance extracellular vesicle-enriched secretome therapies towards clinical use, with an initial focus on osteoarthritis. Led by Exogenus Therapeutics, ExoCordOA brings together ten organisations with complementary expertise across biotechnology, clinical… Read More